Efficacy and safety of first-line immunotherapy in advanced renal cell carcinoma: a systematic review and network meta-analysis. (PubMed, Transl Androl Urol) - Sep 13, 2026 - "Notably, benmelstobart plus anlotinib achieved the highest ORR [odds ratio (OR): 7.55, 95% CI: 3.99-14.28], followed by pembrolizumab plus lenvatinib (OR: 4.18, 95% CI: 2.29-7.61). Other ICI plus tyrosine kinase inhibitor (TKI) combinations and nivolumab plus ipilimumab also significantly improved OS compared to sunitinib...However, these global rankings from pooled cohorts should not be interpreted as absolute clinical recommendations for all subgroups. Real-world treatment selection must be highly individualized and strictly tailored to the patient's specific International Metastatic RCC Database Consortium (IMDC) risk profile alongside the efficacy-safety trade-off."
Journal • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IFNA1 • IL2
|
|
Guanyi Chen; Tengwei Su; Yongliang Jin
|